- TRADE NAME: Rayaldee (Opko)
- INDICATIONS: Hyperparathyroidism in stage 3 or 4 chronic kidney disease
- SYNONYM: calcidiol
- CLASS: Vitamin D analog
- HALF-LIFE: 11 days
- FDA APPROVAL DATE: 06/17/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticonvulsants, Atazanavir, Cholestyramine, Clarithromycin, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenobarbital, Ritonavir, Saquinavir, Telithromycin, Thiazides, Voriconazole
Please login to view the rest of this drug profile.
Page last updated 11/01/2024
